Stromal Gene Signatures in Large-B-Cell Lymphomas


ABSTRACT

BACKGROUND
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear.

METHODS
We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression–based survival-predictor model derived from a training group was tested in a validation group.

RESULTS
A multivariate model created from three gene-expression signatures — termed “germinal-center B-cell,” “stromal-1,” and “stromal-2” — predicted survival both in patients who received CHOP and patients who received R-CHOP. The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration. By contrast, the prognostically unfavorable stromal-2 signature reflected tumor blood-vessel density.

CONCLUSIONS
Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
Although diffuse large-B-cell lymphoma is curable with anthracycline-based chemotherapy regimens such as a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), the addition of rituximab immunotherapy (R-CHOP) has improved overall survival among patients with diffuse large-B-cell lymphoma by 10 to 15%. Diffuse large-B-cell lymphoma is a molecularly heterogeneous disease, and it is unclear whether rituximab preferentially improves the outcome in certain subgroups of patients.

Gene-expression profiling has identified two biologically and clinically distinct molecular subtypes of diffuse large-B-cell lymphoma. The germinal-center B-cell–like diffuse large-B-cell lymphoma subtype probably arises from normal germinal-center B cells, whereas the activated B-cell–like subtype may arise from a post-germinal-center B cell that is blocked during plasma-cell differentiation. Many oncogenic mechanisms distinguish these subtypes: germinal-center B-cell–like diffuse large-B-cell lymphomas have recurrent t(14;18) translocations, whereas activated B-cell–like diffuse large-B-cell lymphomas have recurrent trisomy 3 and deletion of the inhibitor of kinase 4A–alternative reading frame (INK4A/ARF) locus as well as constitutive activation of the antiapoptotic nuclear factor (NF)-κB signaling pathway. With CHOP-like chemotherapy, the 5-year overall survival rates among patients with germinal-center B-cell–like diffuse large-B-cell lymphoma and those with activated B-cell–like diffuse large-B-cell lymphoma were 60% and 30%, respectively.

A different analytic approach identified four gene-expression signatures that reflected distinct biologic attributes of diffuse large-B-cell lymphoma tumors that were associated with survival among patients who received CHOP. A “germinal-center B-cell” signature was associated with a favorable prognosis and paralleled the distinction between activated B-cell–like and germinal-center B-cell–like diffuse large-B-cell lymphoma. The “proliferation” signature was associated with a poor prognosis and included MYC and its target genes. The “major histocompatibility complex (MHC) class II” signature was silenced in the malignant cells in a subgroup of patients with diffuse large-B-cell lymphoma; this event was associated with inferior survival. A fourth prognostic signature, termed “lymph node,” was associated with a favorable prognosis and included components of the extracellular matrix, suggesting that it may reflect the nature of the tumor microenvironment. These signatures predicted survival in a statistically independent fashion, indicating that multiple biologic variables dictate the response to CHOP chemotherapy in diffuse large-B-cell lymphoma.

To evaluate the biologic basis of survival after therapy for diffuse large-B-cell lymphoma, we profiled gene expression in pretreatment biopsy samples obtained from patients treated with CHOP or R-CHOP. We used these data to search for gene-expression signatures of different aspects of tumor biology that were associated with survival.

**METHODS**

**STUDY POPULATIONS**

Pretreatment tumor-biopsy specimens and clinical data were obtained from 414 patients with newly diagnosed diffuse large-B-cell lymphoma who were treated at 10 institutions in North America and Europe and studied according to a protocol approved by the institutional review board of the National Cancer Institute. Among these patients, a CHOP training group consisted of 181 patients, previously described, who were treated with anthracycline-based combinations, most often CHOP or similar regimens. The other 233 patients constituted an R-CHOP cohort that received similar chemotherapy plus rituximab. The median follow-up for the R-CHOP cohort was 2.1 years; the median follow-up for survivors was 2.8 years. A panel of expert hematopathologists confirmed the diagnosis of diffuse large-B-cell lymphoma using current World Health Organization criteria. We also analyzed data from a second cohort of 177 patients who received CHOP; these data were previously reported by the Molecular Mechanisms in Malignant Lymphomas Network Project (MMMLNP).

**GENE-EXPRESSION PROFILING**

Gene-expression profiling was performed with the use of Affymetrix U133 plus 2.0 microarrays (data available at www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=rhojaiwksaih&acc=GSE10846, accession number GSE10846). Cell suspensions from three biopsy specimens were separated by means of flow cytometry into a CD19+ malignant subpopulation and a CD19– nonmalignant subpopulation. Gene-expression profiling was performed after two rounds of linear amplification from to-
tal RNA. After normalization to a median signal of 500, provided in the Affymetrix Microarray Suite software, version 5.0 (MAS5.0), we selected genes that had a signal value greater than 128 in either the CD19+ or CD19– fractions in at least two of the sorted samples. Detailed statistical and experimental methods are described in the Supplementary Appendix, available with the full text of this article at www.nejm.org.

**STATISTICAL ANALYSIS**

All aspects of identification of the gene-expression signatures and development of the survival model were based solely on the data from the CHOP training group and are outlined in detail in the Supplementary Appendix. No previous survival analysis or subgroup analysis was performed with the validation groups (i.e., the MMMLNP CHOP and the R-CHOP cohorts). A Cox model was used to identify genes associated with survival and to build multivariate survival models. The models and their associated scaling coefficients were fixed, based on the CHOP training group, and then evaluated in the validation groups. All reported P values are two-sided, except those in the validation groups, which are one-sided P values in the direction of the observed effect on the training group. P values reported for survival associations were based on single-hypothesis testing, except those for testing of multivariate models involving the germinal-center B-cell, stromal-1, proliferation, and MHC class II signatures in the R-CHOP cohort, which were not adjusted for multiple testing.

To discover new signatures associated with survival, we selected individual genes with expression patterns that contributed significantly (P<0.01) to the survival association in the CHOP training group, in a model containing that gene and the germinal-center B-cell and stromal-1 signatures. We organized these genes by hierarchical clustering according to their expression levels in the CHOP training group, and we identified five clusters of coordinately expressed genes (r>0.6). For each of these five candidate signatures, we averaged the expression levels of the component genes and tested whether the average for the signature added to the predictive significance of the bivariate survival model for the CHOP training group. One signature was clearly superior to the others with respect to its predictive contribution to the survival model and was therefore chosen for further analysis. This signature also added to the predictive significance of the bivariate model for the R-CHOP cohort (P=0.001) and for the MMMLNP CHOP cohort (P=0.011) (Fig. 8B and 8C in the Supplementary Appendix). In these survival models, this new signature was associated with reduced survival, whereas the stromal-1 signature was associated with increased survival, even though these two signatures were correlated with one another (r>0.8). Therefore, to refine this new signature, we identified genes that were more closely associated with it than with the stromal-1 signature (P<0.02) in the CHOP training group, and we organized these genes into three signatures by hierarchical clustering, as described above. The signature that most improved the survival model (stromal-2) was chosen for subsequent analyses.

**RESULTS**

**MULTIVARIATE MODEL OF SURVIVAL**

We profiled gene expression in 414 pretreatment biopsy samples from patients with newly diagnosed diffuse large-B-cell lymphoma, including a training group of 181 patients treated with CHOP or CHOP-like chemotherapy alone and a validation group of 233 patients treated with similar chemotherapy plus rituximab. In this R-CHOP cohort (Table 1), patients with germinal-center B-cell–like diffuse large-B-cell lymphoma had higher overall and progression-free survival rates than those with activated B-cell–like diffuse large-B-cell lymphoma (Fig. 1A). Three gene-expression signatures that predicted survival in the CHOP training group — termed germinal-center B-cell, lymph-node, and proliferation — were significantly associated with the outcome in a second cohort of CHOP-treated patients (from the MMMLNP) and in the R-CHOP cohort (Fig. 1 and 2 in the Supplementary Appendix). In contrast, the MHC class II signature was not associated with survival in the R-CHOP cohort (Fig. 1, 2, and 3 in the Supplementary Appendix). From these four signatures, an optimal survival model for R-CHOP combined the germinal-center B-cell and lymph-node signatures (Fig. 4A in the Supplementary Appendix). Since this latter signature reflects the tumor microenvironment (see below), we refer to it as “stromal-1.”

We next discovered a new signature that added to the prognostic significance of the bivariate model for the CHOP training group; we call this signature “stromal-2” by virtue of its association
with the tumor microenvironment. The stromal-2 signature added to the predictive significance of the survival model for the R-CHOP cohort (P<0.001) and for the MMMLNP CHOP cohort (P = 0.002). The resulting trivariate model was highly associated with overall and 3-year progression-free survival as a continuous variable in the R-CHOP cohort (P<0.001). Each signature added to the predictive significance of the model, with the germinal-center B-cell and stromal-1 signatures associated with increased survival and the stromal-2 signature associated with reduced survival (Table 2 in the Supplementary Appendix). The survival-predictor score generated by this model was associated with an increase in the relative risk of death of 2.76 (95% confidence interval, 1.90 to 3.90) per unit increment of the score, which varied over 3.58 units and had a standard deviation of 0.76 in the R-CHOP cohort. Model scores were used to divide the R-CHOP cohort into quartiles of 3-year overall survival rates of 89%, 82%, 74%, and 48% and 3-year progression-free survival rates of 84%, 69%, 61%, and 33% (Fig. 1B).

When combined with the International Prognostic Index (IPI), the gene-expression–based model added to the predictive power of the gene-expression–based model (P = 0.0033), suggesting that survival in diffuse large-B-cell lymphoma is influenced both by clinical variables and by biologic features of the lymphoma (Fig. 4B and 5 in the Supplementary Appendix).

**Table 1. Clinical Characteristics of Patients with Diffuse Large-B-Cell Lymphoma Treated with R-CHOP.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Subtypes (N = 233)</th>
<th>Germinal Center B-Cell-like Subtype (N = 107)</th>
<th>Activated B-Cell-like Subtype (N = 95)</th>
<th>Unclassified Subtype (N = 33)</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;60 yr</td>
<td>122/233 (52)</td>
<td>50/107 (47)</td>
<td>59/93 (63)</td>
<td>13/33 (39)</td>
<td>0.023</td>
</tr>
<tr>
<td>Ann Arbor stage &gt;II‡</td>
<td>121/226 (54)</td>
<td>49/103 (48)</td>
<td>56/91 (62)</td>
<td>16/32 (50)</td>
<td>0.061</td>
</tr>
<tr>
<td>Lactate dehydrogenase &gt;ULN</td>
<td>93/192 (48)</td>
<td>38/89 (43)</td>
<td>44/76 (58)</td>
<td>11/27 (41)</td>
<td>0.062</td>
</tr>
<tr>
<td>≥2 Extramedial sites</td>
<td>30/204 (15)</td>
<td>13/92 (14)</td>
<td>13/84 (15)</td>
<td>4/28 (14)</td>
<td>0.834</td>
</tr>
<tr>
<td>ECOG performance status &gt;1§</td>
<td>52/210 (25)</td>
<td>17/98 (17)</td>
<td>27/82 (33)</td>
<td>8/30 (27)</td>
<td>0.023</td>
</tr>
<tr>
<td>IPI score¶</td>
<td>75/182 (41)</td>
<td>47/85 (55)</td>
<td>15/71 (21)</td>
<td>13/26 (50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>0 or 1</td>
<td>83/182 (46)</td>
<td>28/85 (33)</td>
<td>45/71 (63)</td>
<td>10/26 (38)</td>
<td></td>
</tr>
<tr>
<td>2 or 3</td>
<td>24/182 (13)</td>
<td>10/85 (12)</td>
<td>11/71 (15)</td>
<td>3/26 (12)</td>
<td></td>
</tr>
</tbody>
</table>

* R-CHOP denotes rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, and ULN upper limit of the normal range.
† P values are for the comparison of activated B-cell–like and germinal-center B-cell–like diffuse large-B-cell lymphomas.
‡ The Ann Arbor staging system ranges from I to IV, with a higher stage indicating more widespread disease.
§ The Eastern Cooperative Oncology Group (ECOG) performance score ranges from 0 to 3, with a higher score indicating greater impairment.
¶ The International Prognostic Index (IPI) score ranges from 0 to 5, with 0 indicating the absence of all prognostic factors and 5 indicating the presence of all prognostic factors.
Survival in Diffuse Large-B-Cell Lymphoma

The biologic attributes of the tumor microenvironment that can be acquired during the pathogenesis of both diffuse large-B-cell lymphoma subtypes (Fig. 3).

The genes defining the stromal-1 signature encode components of the extracellular matrix, including fibronectin, osteonectin, various collagen and laminin isoforms, and the antiangiogenic factor thrombospondin (Fig. 3, and Table 3 in the Supplementary Appendix). This signature also encodes modifiers of collagen synthesis (LOXL1 and SERPINH1), proteins that remodel the extracellular matrix (MMP2, MMP9, MMP14, PLAU, and TIMP2), and connective-tissue growth factor (CTGF), a secreted protein that can initiate fibrotic responses.16 In addition, the stromal-1 signature includes genes that are characteristically expressed in cells in the monocytic lineage, such as CEBPA and CSF2RA.

The stromal-1 signature was significantly related to several previously curated gene-expression signatures17 on the basis of gene-set enrichment analysis.18 Two of these signatures include genes...
that are coordinately expressed in normal mesenchymal tissues but not in hematopoietic subgroups, many of which encode extracellular-matrix proteins (false discovery rate, <0.001) (Fig. 2B, and Fig. 6A in the Supplementary Appendix).19 Also enriched was a “monocyte” signature, comprising genes that are more highly expressed in CD14+ blood monocytes than in B cells, T cells, or natural killer cells (false discovery rate, 0.014) (Fig. 2B, and Fig. 6B in the Supplementary Appendix). By contrast, a pan–T-cell signature was not related to the stromal-1 signature (Fig. 2B, and Fig. 6B in the Supplementary Appendix). These findings suggest that high expression of the stromal-1 signature identifies tumors with vigorous extracellular-matrix deposition and infiltration by cells of the monocytic lineage.

Several stromal-2 signature genes encode well-known markers of endothelial cells, including von Willebrand factor and CD31 (platelet endothelial-cell adhesion molecule, or PECAM1), as do other genes specifically expressed in endothelium such as EGFL7, MMRN2, GPR116, and SPARC1L (Table 3 in the Supplementary Appendix). This signature also includes genes encoding key regulators of angiogenesis: kinase-domain-related (KDR) receptor (vascular endothelial growth factor [VEGF] receptor 2); GRB10 (growth factor receptor–bound
lar-matrix formation (Fig. 4A). By contrast, the lymphoma, in keeping with its role in extracellular matrix, a component of the stromal-1 signature, was prominently localized in fibrous strands running between the malignant cells in biopsy samples obtained from patients with diffuse large-B-cell lymphoma (Fig. 4B, 4C, and 4D). On immunohistochemical staining, fibronec-tin, a component of the stromal-1 signature, was primarily localized in fibrous strands running between the malignant cells in biopsy samples obtained from patients with diffuse large-B-cell lymphoma, in keeping with its role in extracellular-matrix structure formation (Fig. 4A). By contrast, the protein products of three other stromal-1 genes — MMP9, SPARC, and CTGF — were localized primarily in histiocytic-cell infiltrates in the biopsy specimens from patients with diffuse large-B-cell lymphoma (Fig. 4B, 4C, and 4D). On immunofluorescence analysis, SPARC and CTGF colocalized with CD68, a marker for cells in the monocytic lineage (Fig. 4E and 4F). As expected for a stromal-1 gene product, higher SPARC protein levels were associated with increased overall survival (Fig. 4G). Thus, the stromal-1 signature reflects a monocyte-rich host reaction to the lymphoma that is associated with abundant deposition of extracellular matrix.

Finally, we suspected that high relative expression of the stromal-2 signature (i.e., a high stromal score) would reflect high tumor blood-vessel density, given the connection between many stromal-2 signature genes and angiogenesis. Indeed, a quantitative measure of blood-vessel density correlated significantly with the stromal score (r=0.483, P=0.021) (Fig. 4H, 4I, and 4J).

**DISCUSSION**

Biologic variation among diffuse large-B-cell lymphoma tumors, as measured by means of gene-expression signatures, has a consistent relationship to treatment response, regardless of the regimen used. Specifically, the benefit of rituximab immunotherapy combined with chemotherapy was evident in both the activated B-cell–like and germinal-center B-cell–like subtypes of diffuse large-B-cell lymphoma (Fig. 1A, and Fig. 7 in the Supplementary Appendix). Moreover, several other gene-expression signatures that predicted survival among patients who received CHOP chemotherapy retained their prognostic power among patients who received R-CHOP. Hence, future clinical trials in diffuse large-B-cell lymphoma should incorporate quantitative methods to discern these biologic differences so that patient cohorts in different trials can be compared and treatment responses can be related to defined tumor phenotypes.

The survival model includes two gene-expression signatures, stromal-1 and stromal-2, that reflect the character of the nonmalignant cells in diffuse large-B-cell lymphoma. The stromal-1 signature includes genes that are coordinately expressed in many normal mesenchymal tissues, most of which encode proteins that form or modify the extracellular matrix. One stromal-1 signature component, fibronectin, was localized to fibrous strands insinuated between the malignant lymphoma cells, suggesting that this signature reflects the fibrotic nature of many diffuse large-B-cell lymphomas. A key to this fibrotic reaction may be another stromal-1 signature component, CTGF, which participates in many fibrotic responses and diseases. CTGF also promotes tumor growth and metastasis of epithelial cancers.22 Another characteristic feature of tumors with high expression of the stromal-1 signature was infiltration by cells of the myeloid lineage. Various cells in this lineage have been implicated in the pathogenesis of epithelial cancers, including tumor-associated macrophages, myeloid-derived suppressor cells, and Tie2-expressing monocytes.23 In animal models, these cells promote tumor-cell invasion by secreting matrix metalloproteinases such as MMP9 (Fig. 4B), suppress T-cell immune responses, and initiate angiogenesis.

The stromal-2 signature may be an “angiogenic switch” in which the progression of a hyperplastic lesion to a fully malignant tumor is accompanied by new blood-vessel formation.24 We observed that diffuse large-B-cell lymphomas with high relative expression of the stromal-2 signature were associated with increased tumor blood-vessel density and an adverse outcome. Given the complex interplay of cells and cytokines that regulate
neoangiogenesis in tumors, an understanding of the mechanism of angiogenesis in diffuse large-B-cell lymphoma must await the development of animal models that recapitulate the stromal biology of the human tumors that is revealed by the stromal-1 and stromal-2 signatures. Nonetheless, some aspects of the stromal phenotypes of diffuse large-B-cell lymphoma suggest angiogenic mechanisms. First, the macrophage infiltration in some diffuse large-B-cell lymphomas may confer a predisposition to angiogenesis, since in experimental models, tumor-associated macrophages accumulate before the angiogenic switch and are required for the switch to occur. Second, CXC chemokine ligand 12 (CXCL12) (also called stromal-cell–derived factor 1, or SDF-1), a stromal-2 signature component, is a chemokine secreted by either fibroblasts or endothelial cells that can promote angiogenesis by recruiting CXCR4+ endothelial precursor cells from the bone marrow. Third, an antagonist of angiogenesis, thrombospondin-2, is a stromal-1 signature component, which may explain why tumors with low relative expression of this signature had an elevated blood-vessel density. Finally, the expression of adipocyte-associated genes in diffuse large-B-cell lymphomas with high stromal-2 signature expression may play a role in angiogenesis, since some cells in...
Survival in Diffuse Large-B-Cell Lymphoma

The monoclonal antibody to VEGF, bevacizumab, is currently being investigated in several phase 2 and phase 3 clinical trials involving patients with diffuse large-B-cell lymphoma. On the basis of our results, it is possible that only a subgroup of such patients — those with diffuse large-B-cell lymphoma characterized by high relative expression of the stromal-2 signature and increased tumor blood-vessel density — may benefit from this angiogenesis inhibitor. Given the proangiogenic function of SDF-1, small-molecule inhibitors of its receptor, CXCR4, may have activity in diffuse large-B-cell lymphoma.

Panels A–D show the expression of genes associated with the stromal-1 and stromal-2 signatures. Panel E shows colocalization of SPARC and CTGF with the myelomonocytic marker CD68. Panel G shows Kaplan–Meier estimates of overall survival according to the level of expression of SPARC. Panels H and I show tumor blood-vessel density according to immunohistochemical analysis of CD34+ endothelial cells in biopsy specimens. Representative cases with low or high blood-vessel density (CD34+ cells per µm²) are shown. Panel J shows the correlation between tumor blood-vessel density and the stromal score.

The biologic insights gained from our analysis provide a new perspective on current and future clinical trials in diffuse large-B-cell lymphoma. The monoclonal antibody to VEGF, bevacizumab, may have the potential to differentiate into endothelial cells. Alternatively, the expression of adipose-associated genes may reflect the recruitment of bone marrow–derived mesenchymal stem cells, which home efficiently to tumors and can stabilize newly formed blood vessels.

**Figure 4. Immunohistochemical Analysis of Biopsy Specimens from Patients with Diffuse Large-B-Cell Lymphoma.**

Panel A shows that fibronectin, a stromal-1 signature component, was localized prominently in fibrous strands running between malignant cells in the biopsy specimens. Panels B, C, and D show matrix metalloproteinase 9 (MMP9), secreted protein acidic cysteine-rich (SPARC), and connective-tissue growth factor (CTGF), respectively. Each of these components of the stromal-1 signature was localized primarily in histiocytic cells infiltrating the biopsy specimens. Panels E and F show colocalization of SPARC and CTGF with the myelomonocytic marker CD68. Panel G shows Kaplan–Meier estimates of overall survival according to the level of expression of SPARC. Panels H and I show tumor blood-vessel density according to immunohistochemical analysis of CD34+ endothelial cells in biopsy specimens. Representative cases with low or high blood-vessel density (CD34+ cells per µm²) are shown. Panel J shows the correlation between tumor blood-vessel density and the stromal score.
large-B-cell lymphoma.\textsuperscript{32} The heavy infiltration of some diffuse large-B-cell lymphomas with myeloid-lineage cells raises the possibility that monoclonal antibodies targeting antigens on the myeloid-lineage cells could interfere with trophic interactions between these cells and malignant cells. Antibodies to CTGF have shown activity in preclinical models of cancer\textsuperscript{33} and might interfere with microenvironmental interactions in diffuse large-B-cell lymphoma. Ultimately, combined treatments that target oncogenic mechanisms in the malignant cell as well as interactions in the tumor microenvironment may prove to be synergistic.

Supported by grants from the Intramural Research Program of the National Institutes of Health, the National Cancer Institute (NCI), and the Center for Cancer Research; an NCI Strategic Partnering to Evaluate Cancer Signature grant (U01-CA 114778); and a grant from the German Research Foundation (to Dr. Lenz).

Dr. Vose reports receiving grant support from Genentech; Dr. Greiner, lecture fees from Imexed Future; Dr. Armitage, consulting fees from Zopapharm, L'Oreal, Celgene, Genitope, and Biogen Idec and lecture fees from Genentech; Dr. Gascoyne, consulting fees from Genentech and Roche Canada and lecture fees and grant support from Roche Canada; Dr. Connors, grant support from Roche Canada; Dr. Montserrat, consulting fees from Schering and Hoffmann-La Roche; Dr. Müller, consulting fees and grant support from Genentech and Biogen Idec; Dr. Rimsza, grant support from Ventana Medical Systems; Dr. Cook, consulting fees from Roche Molecular Systems; Dr. Pohlmam, consulting fees from Genentech BioOncology and grant support from Genentech BioOncology National Lymphcare Study; Dr. Fisher, consulting fees from Allos Therapeutics, Millennium, Amgen, Pharmion, Celgene, Roche, Genentech, and Seattle Genetics; Dr. Lister, consulting fees from Medex, Ilexos, Educational Concepts, Genentech, and Upside Endavors and grant support from Millenium; and Dr. Chan, grant support from Roche Molecular Systems. No other potential conflict of interest relevant to this article was reported.

We thank Alexander Kohlmann, Mickey Williams, and Lothar Wieczorek at Roche Molecular Systems for logistical support.

\section*{Appendix}

From the Metabolism Branch (G.L., S.S.D., H.Z., W. Xu, B.T., N.G., W.H.W., L.M.S.), Biometric Research Branch, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute; Bioinformatics and Molecular Analysis Section (W. Xiao, J.P.), and Laboratory of Pathology, Center for Cancer Research (E.S.J.), Computational Bioscience and Engineering Laboratory, Center for Information Technology — all at the National Institutes of Health, Bethesda, MD; University of Nebraska Medical Center, Omaha (J.I., J.V., M.B., K.F., D.D.W., T.C.G., J.O.A., W.C.C.); British Columbia Cancer Agency, Vancouver, Canada (A.K., L.M., R.D.G., J.M.C.); Pathology Clinic (G.T., J.D.), Cancer Clinic (H.H., S.K.), and Institute for Cancer Research (E.B.S.), Rikshospitalet University Hospital; and Center for Cancer Biomedicine, Faculty Division of the Norwegian Radium Hospital, University of Oslo (E.B.S.) — both in Oslo; University of Leuven, Department of Hematology, Leuven, Belgium (D.D., G.V.); Hospital Clinic, University of Barcelona, Barcelona (P.J., A.M., A.L.G., E.M., E.C.); Oregon Health and Science University, Portland (R.M.B.); Southwest Oncology Group (R.M.B., T.P.M., L.M.R., J.R.C., R.R.T., R.L.F.) and University of Arizona Cancer Center (T.P.M., L.M.R.) — both in Tucson; Cleveland Clinic Taussig Cancer Institute (B.P., I.S.) and Cleveland Clinic Pathology and Laboratory Medicine Institute (J.R.C., R.R.T.) — both in Cleveland; James P. Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York (R.I.F.); Department of Pathology, University of Würzburg, Würzburg, Germany (E.H., A.R., G.O., H.-K.M.-H.); Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany (G.O.); and Cancer Research UK, St. Bartholomew’s Hospital, London (D.W., T.A.L.).

\section*{References}